Apixaban Outperforms Rivaroxaban for VTE Treatment

Recurrent venous thromboembolism and bleeding was less common with apixaban, but differences were small.

Recent cohort studies have shown that apixaban yields slightly better efficacy and safety outcomes than does rivaroxaban in patients with atrial fibrillation (NEJM JW Gen Med Apr 1 2020 and Ann Intern Med 2020; 172:463). However, outcomes in patients with venous thromboembolism (VTE) are unknown. Investigators used a retrospective propensity-matched cohort to compare >37,000 patients who initiated either apixaban or rivaroxaban therapy for VTE (i.e., proximal deep venous thrombosis [DVT] or pulmonary embolism [PE]). Median follow-up was ≈3 months.

Compared with rivaroxaban recipients, apixaban recipients had significantly lower rates of recurrent VTE (risk differences at 2 months and 6 months: 0.6% and 1.1%) and significantly lower rates of …

Reviewing Author

Daniel D. Dressler, MD, MSc, MHM, FACP

Disclosures

RoyaltiesMcGraw-Hill; Elsevier

Editorial BoardsMedical Clinics of North America; Caribbean Medical Journal International Advisory Panel (2021–2026)

Daniel D. Dressler, MD, MSc, MHM, FACP

Disclosures

RoyaltiesMcGraw-Hill; Elsevier

Editorial BoardsMedical Clinics of North America; Caribbean Medical Journal International Advisory Panel (2021–2026)

Apixaban Outperforms Rivaroxaban for VTE Treatment

Topics

Reviewing Author